A Phase 2 interventional study of Lidocaine/Diphenhydramine and lidocaine in Vulvodynia, sponsored by Lumara Health, Inc.. Completed at 48 sites in 2 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-03-02.
Sponsored by Lumara Health, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Vulvodynia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Vulvodynia · United States.
Among the 47 studies in Vulvodynia with a site in United States, this one is the 6th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2007, is one of 10 in phase 2, and was the 6th registered.
117 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.
Browse Vulvodynia studies →8 of the 47 studies in Vulvodynia with a site in United States are open now. Recruiting first, the newest first:
Center for Vulvovaginal Disorders · Sites in United States
Ages 18+ · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
Center for Vulvovaginal Disorders · Sites in United States
Ages 18+ · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
Texas Tech University Health Sciences Center · Sites in United States
Ages 21–75 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Vulvodynia studies recruiting now, 8 (62%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 5 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 46 across 89 interventional studies indexed under Vulvodynia.
Median enrollment 45 across the 36 interventional studies, 168 across the 11 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 47 have an industry lead sponsor. The 10 most frequent:
Lumara Health, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Lumara Health, Inc. has 1 study filed under Vulvodynia — fewer than ten, so there is no comparison to draw.
6 of the studies in Vulvodynia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486830Center for Vulvovaginal DisordersIncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction | 2026-12-20 |
| NCT07401134University of MiamiImproving Postoperative Recovery: A Study of Multimodal Perineal Analgesia Protocol (MPAP) After Vaginal Surgery | 2027-01 |
| NCT05343182Oregon Health and Science UniversityVestibulectomy Surgical Techniques Comparison Study | 2027-04 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
| NCT01829204Texas Tech University Health Sciences CenterProspective Data Bank Creation to Study Vaginal Conditions | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 47 studies in Vulvodynia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of two vaginal products compared with that of placebo to determine if the two products are better than placebo in the relief of vaginal discomfort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: placebo
Drug: lidocaine
Drug: Lidocaine/Diphenhydramine
Drug pages: Lidocaine · Diphenhydramine
semi solid, twice weekly, 4 months
semi solid, twice weekly for 4 months
semi solid, twice weekly for 4 months
Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks)
The MDSS consists of a participant rating of their dyspareunia (painful sexual intercourse) on a 0- to 3-point scale. Each numerical value on the scale coincides with a level of pain experienced during sexual intercourse; 0 = no dyspareunia (no pain with intercourse) and 3 = completely prevents intercourse
Time frame: 12 weeks
Change From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks)
0-3 scale with 0=no dyspareunia and 3= completely prevents intercourse
Time frame: Baseline -12 Weeks
Change From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort]
Time frame: 12 Weeks
Change From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain]
Time frame: 12 weeks
Change From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be]
Time frame: 12 Weeks
Change From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe]
Time frame: 12 Weeks
Participants were recruited from 31 physician offices in the US and Canada between 04Sep2007 to 18Mar2009.
| Milestone | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| Started | 39 | 39 | 27 |
| Completed | 32 | 33 | 21 |
| Not completed | 7 | 6 | 6 |
| Withdrew: Lack of efficacy | 1 | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 4 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Did not complete due to study closure | 1 | 1 | 1 |
| Withdrew: Did not complete study | 0 | 1 | 0 |
The MDSS consists of a participant rating of their dyspareunia (painful sexual intercourse) on a 0- to 3-point scale. Each numerical value on the scale coincides with a level of pain experienced during sexual intercourse; 0 = no dyspareunia (no pain with intercourse) and 3 = completely prevents intercourse
| scores on a scale | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks) | 1.8 ± 0.12 | 1.8 ± 0.12 | 1.7 ± 0.14 |
0-3 scale with 0=no dyspareunia and 3= completely prevents intercourse
| Score | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| Change From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks) | -0.6 ± 0.15 | -0.4 ± 0.13 | -0.7 ± 0.15 |
| Score | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| Change From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort] | -9.9 ± 3.48 | -3.8 ± 4.46 | -14.6 ± 4.56 |
| Score | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| Change From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain] | -10.3 ± 5.71 | -19.6 ± 4.42 | -19.3 ± 6.55 |
| Score | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| Change From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be] | -10.4 ± 4.31 | -5.3 ± 4.47 | -16.3 ± 4.22 |
| Score | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| Change From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe] | -3.0 ± 0.70 | -1.7 ± 0.67 | -2.4 ± 0.75 |
Collected over 16 weeks for each subject. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lidocaine/Diphenhydramine (Combination) | — | 0/39 (0%) | 30/39 (76.9%) |
| Lidocaine | — | 0/39 (0%) | 30/39 (76.9%) |
| Placebo | — | 0/27 (0%) | 23/27 (85.2%) |
| Event | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/39 | 4/39 | 6/27 |
| HeadacheNervous system disorders | 8/39 | 5/39 | 3/27 |
| DysmenorrhoeaReproductive system and breast disorders | 3/39 | 4/39 | 4/27 |
| Vulvovaginal burning sensationReproductive system and breast disorders | 4/39 | 3/39 | 4/27 |
| Vulvovaginal pruritusReproductive system and breast disorders | 1/39 | 5/39 | 1/27 |
| Fungal infectionInfections and infestations | 3/39 | 4/39 | 2/27 |
| Vaginal candidiasisInfections and infestations | 2/39 | 4/39 | 2/27 |
| Vulvovaginal discomfortReproductive system and breast disorders | 3/39 | 4/39 | 1/27 |
| Urinary tract infectionInfections and infestations | 1/39 | 3/39 | 1/27 |
| Vaginal DischargeReproductive system and breast disorders | 3/39 | 2/39 | 1/27 |
| Age, Categorical(Participants) | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 39 | 39 | 27 | 105 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age Continuous(years) | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo | Total |
|---|---|---|---|---|
| Mean | 30 ± 7.4 | 32 ± 9.0 | 32 ± 9.5 | 31 ± 8.5 |
| Sex: Female, Male(Participants) | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo | Total |
|---|---|---|---|---|
| Female | 39 | 39 | 27 | 105 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Lidocaine/Diphenhydramine (Combination) | Lidocaine | Placebo | Total |
|---|---|---|---|---|
| United States | 36 | 39 | 25 | 100 |
| Canada | 3 | 0 | 2 | 5 |
The record gives a start of Oct 2007, a primary completion of Jun 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lidocaine · Diphenhydramine
Lumara Health, Inc.